| Autor: |
Bankhead, Charles |
| Předmět: |
|
| Zdroj: |
Urology Times; Dec2009, Vol. 37 Issue 13, p14-17, 2p |
| Abstrakt: |
The article reports on the study which suggests that intermittent androgen ablation does not improve survival or quality of life compared with continuous hormonal therapy to people with metastatic prostate cancer. It notes that the study found out that average survival was four years with maximum androgen suppression and 3.5 years to intermittent therapy. It mentions intermittent androgen ablation shows promise for prostate cancer treatment but it did not achieve great statistical significance. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
